Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescences with cystic fibrosis

Altabee, Rana, Carr, Siobhán B., Abbott, Janice, Cameron, Rory ORCID: https://orcid.org/0000-0002-7442-0935, Office, Daniel, Simmonds, Nicholas J., Whitty, Jennifer A. ORCID: https://orcid.org/0000-0002-5886-1933, Turner, David ORCID: https://orcid.org/0000-0002-1689-4147 and Barton, Garry (2024) Evaluating the correspondence between the EQ-5D-5L and disease severity and quality of life in adults and adolescences with cystic fibrosis. Respiratory Medicine and Research. ISSN 2590-0412

Microsoft Word (OpenXML) (Quality_Of_Life_in_CF_120623_final_draft_v.2.2) - Accepted Version Available under License Creative Commons Attribution. Download (112kB)

Abstract

Background: The EQ-5D is the recommended measure to capture health-related quality of life (HRQoL), recognised for use in health technology appraisal bodies. In order to assess whether it is appropriate to use the EQ-5D for making decisions about the cost-utility of treatments in cystic fibrosis (CF), this study assesses the performance of the EQ-5D-5L in adults and adolescents with CF.   Method: This was a cross-sectional observational survey study of patients with CF attending a single large CF centre. Participants were asked to complete a survey that included two HRQoL measures; the EQ-5D-5L and CF Quality of Life (CFQoL) questionnaires.   Results: Among 213 participants, the median EQ-5D-5L index score was 0.76 (IQR 0.66 – 0.84) and the visual analogue (EQ-VAS) was 70 (60 – 80). Both the EQ-5D index and EQ-VAS discriminated between disease severity based on lung function (p=0.01 and p<0.01, respectively) and pulmonary exacerbation (p=0.02 and p<0.01, respectively); however, EQ-VAS differentiated between more lung function severity groups compared to EQ-5D index. The EQ-5D-5L demonstrated convergent validity as its dimensions, index score, and EQ-VAS had significant correlations with most CFQoL domains. Though, EQ-VAS significantly predicted more domains of CFQoL (4 domains) compared to EQ-5D index (only 1 domain).   Conclusion: The generic EQ-5D-5L performed adequately in discriminating between CF disease severity, and its index score and EQ-VAS had moderate correlations with CFQoL. However, using a complementary condition-specific measure alongside the EQ-5D-5L can provide better insight of HRQoL in CF and benefit the process of cost-utility analysis.

Item Type:	Article
Uncontrolled Keywords:	cystic fibrosis,quality of life,health-related quality of life,patient-reported outcomes
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Centres > Norwich Institute for Healthy Aging Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Centres > Population Health Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit
Depositing User:	LivePure Connector
Date Deposited:	20 Aug 2024 13:30
Last Modified:	06 Sep 2024 01:41
URI:	https://ueaeprints.uea.ac.uk/id/eprint/96284
DOI:	10.1016/j.resmer.2024.101137

Downloads

Actions (login required)

View Item